Activity Refinement and Property Assessment of Peptidomimetics with Potent Antimalarial Activity That Target Plasmepsin V
ACS Infectious Diseases · 11.09.2026 · 12 (9) · 3114-3126
DOI: 10.1021/acsinfecdis.6c00314 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 15.08.2026. Verfasst von Gregory L Adams und 12 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co., Inc., West Point, Pennsylvania19486, United States. Hauptthemen laut MEDLINE: Antimalarials, Aspartic Acid Endopeptidases, Peptidomimetics, Plasmodium falciparum. Die Arbeit nennt 56 Literaturangaben. Gefördert von: Wellcome Trust, National Health and Medical Research Council, University of Melbourne.
Abstract (Originalsprache)
Plasmepsin V is an essential aspartyl protease that cleaves the Plasmodium export element in proteins targeted for export from Plasmodium parasites into the host red blood cell. Substrate-mimicking peptidomimetics have been developed that potently inhibit plasmepsin V but show modest parasite activity. To advance these inhibitors, we optimized their potency by introducing a 2-chloro aryl group at P2 and an N-terminal sulfonamide that yielded WM960, which showed markedly improved plasmepsin V inhibition while retaining high selectivity over plasmepsin IX and X and human aspartyl proteases. WM960 also demonstrated enhanced activity against asexual blood-stage parasites and effectively suppressed protein export. However, WM960 displayed low metabolic stability and limited systemic exposure in mice, highlighting the need to improve pharmacokinetic properties in future development of peptidomimetic plasmepsin V targeted antimalarials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Merck & Co., Inc., West Point, Pennsylvania19486, United States.
- The Walter and Eliza Hall Institute of Medical Research , Parkville3052, Australia.
- Department of Medical Biology, The University of Melbourne, Parkville3010, Australia.
ORCID-Profile: Gregory L Adams, Madeline G Dans, Wenyin Su, Justin A Boddey, Brad E Sleebs
Förderung
- Wellcome Trust
- National Health and Medical Research Council
- University of Melbourne
Zitieren
APA
Adams, G. L., Dans, M. G., Zhou, Q., Su, W., Ngo, A., Jarman, K. E., Fawaz, M. V., Kelly, M. J., McCauley, J. A., Olsen, D. B., Boddey, J. A., Cowman, A. F., & Sleebs, B. E. (2026). Activity Refinement and Property Assessment of Peptidomimetics with Potent Antimalarial Activity That Target Plasmepsin V. ACS Infectious Diseases, 12(9), 3114-3126. https://doi.org/10.1021/acsinfecdis.6c00314
Vancouver
Adams GL, Dans MG, Zhou Q, Su W, Ngo A, Jarman KE, et al. Activity Refinement and Property Assessment of Peptidomimetics with Potent Antimalarial Activity That Target Plasmepsin V. ACS Infectious Diseases. 2026;12(9):3114-3126. doi:10.1021/acsinfecdis.6c00314
BibTeX
@article{Adams2026,
author = {Adams, Gregory L and Dans, Madeline G and Zhou, Qingmiao and Su, Wenyin and Ngo, Anna and Jarman, Kate E and Fawaz, Maria V and Kelly, Michael J and McCauley, John A and Olsen, David B and Boddey, Justin A and Cowman, Alan F and Sleebs, Brad E},
title = {Activity Refinement and Property Assessment of Peptidomimetics with Potent Antimalarial Activity That Target Plasmepsin V},
journal = {ACS Infectious Diseases},
year = {2026},
volume = {12},
number = {9},
pages = {3114--3126},
doi = {10.1021/acsinfecdis.6c00314}
}
EUVIMED